Yi Ping Rong
Vermögen: 48 259 $ am 30.06.2026
Vermögen: 48 259 $ am 30.06.2026
Yi Ping Rong is Executive Director & Senior Vice President at Harbour BioMed (Shanghai) Co., Ltd. since 2016.
Dr. Rong is Executive Director, Chief Scientific Officer & SVP at HBM Holdings Ltd. since 2022.
Former roles include Member at The American Association of Cancer Research.
Education includes a doctorate from Case Western Reserve University conferred in 2008 and a graduate degree from East China University of Science & Technology conferred in 2002.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 05.09.2025 | 36 250 ( 0 % ) | 48 259 $ | 30.06.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| HBM HOLDINGS LIMITED | Technik-/Wissenschafts-/F&E-Leiter | 05.05.2022 |
Harbour BioMed (Shanghai) Co., Ltd.
Harbour BioMed (Shanghai) Co., Ltd. BiotechnologyHealth Technology Engages in discovering and developing innovative therapeutics for cancer | Direktor/Vorstandsmitglied | - |
| Unternehmen | Position | Ende |
|---|---|---|
The American Association of Cancer Research | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
Case Western Reserve University
Case Western Reserve University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
East China University of Science & Technology
East China University of Science & Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harbour BioMed (Shanghai) Co., Ltd.
Harbour BioMed (Shanghai) Co., Ltd. BiotechnologyHealth Technology Engages in discovering and developing innovative therapeutics for cancer | Health Technology |
HBM Holdings Ltd.
HBM Holdings Ltd. Pharmaceuticals: OtherHealth Technology Engages in research and development of therapeutics in the fields of immuno-oncology and immunology diseases | Health Technology |
The American Association of Cancer Research |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen